Heartland Bank & Trust Co Grows Stock Position in Eli Lilly and Company $LLY

Heartland Bank & Trust Co increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 5,004 shares of the company’s stock after purchasing an additional 18 shares during the quarter. Eli Lilly and Company comprises about 1.8% of Heartland Bank & Trust Co’s holdings, making the stock its 11th largest position. Heartland Bank & Trust Co’s holdings in Eli Lilly and Company were worth $3,901,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Precedent Wealth Partners LLC increased its holdings in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK increased its holdings in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $54,000. Duquesne Family Office LLC increased its holdings in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Finally, Corient IA LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $570,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. Finally, Guggenheim increased their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $948.06.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 1.8%

Shares of NYSE LLY opened at $818.60 on Tuesday. The stock has a market cap of $774.77 billion, a P/E ratio of 53.50, a PEG ratio of 1.18 and a beta of 0.47. The business’s fifty day simple moving average is $743.43 and its 200-day simple moving average is $765.54. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.